SCHEMBL4089011

SCHEMBL4089011

CC1CN(CCCN)CCN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC2 Q13490 3/20 0.44
KEAP1 Q14145 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRM1 P11229 2/20 0.38
GRIN2D O15399 2/20 0.36
GRIN3B O60391 2/20 0.36
THRB P10828 2/20 0.36
GRIN1 Q05586 2/20 0.36
GRIN2A Q12879 2/20 0.36
GRIN2B Q13224 2/20 0.36
GRIN2C Q14957 2/20 0.36
GRIN3A Q8TCU5 2/20 0.36
CYP1A2 P05177 2/20 0.36
ALOX15 P16050 2/20 0.36
CYP2C19 P33261 2/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8736330 0.88 BIRC2 (0.46) BIRC2CHRM1GRIN2DGRIN3BTHRB
Tert-Butyl Formate SCHEMBL27742721 0.83 BIRC2 (0.36) BIRC2CHRM1GRIN2DGRIN3BTHRB
Tert-Butyl Formate SCHEMBL27742720 0.83 BIRC2 (0.36) BIRC2CHRM1GRIN2DGRIN3BTHRB
SCHEMBL29509310 0.82 BIRC2 (0.45) BIRC2CHRM1GRIN2DGRIN3BTHRB
SCHEMBL3105772 0.82 BIRC2 (0.45) BIRC2CHRM1GRIN2DGRIN3BTHRB
SCHEMBL22656911 0.82 ACE2 (0.53) BIRC2CHRM1GRIN2DGRIN3BTHRB
SCHEMBL3099250 0.81 EBP (0.47) BIRC2SIGMAR1
SCHEMBL29300888 0.80 BIRC2 (0.46) BIRC2CHRM1GRIN2DGRIN3BTHRB
SCHEMBL4274108 0.79 EBP (0.50) BIRC2SIGMAR1
SCHEMBL3100830 0.79 EBP (0.50) BIRC2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG BIRC2 203/4885KEAP1 242/4885SMN1; SMN2 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.